title: Oncologists want FDA to rethink REMS.
authors.forename: Merrill
authors.initials: M
authors.lastname: Goozner
mesh_terms: D000701:Analgesics, Opioid / Q000627:therapeutic use*; D000747:Anemia, Hypochromic / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D000970:Antineoplastic Agents / Q000009:adverse effects*; D011307:Drug Prescriptions / Q000592:standards*; D005069:Evaluation Studies as Topic; D006084:Graft Rejection / Q000139:chemically induced / Q000276:immunology; D006397:Hematinics / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D010817:Physician-Patient Relations; D019966:Substance-Related Disorders / Q000209:etiology / Q000517:prevention & control*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000701:Analgesics, Opioid; D000970:Antineoplastic Agents; D006397:Hematinics